A Phase 2 interventional study of Placebo and PF-00734200 10 mg QD in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 79 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-06-24.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 303 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Placebo
Drug: PF-00734200 10 mg QD
Drug: PF-00734200 20 mg QD
Drug: PF-00734200 5 mg QD
Drug: PF-00734200 2 mg QD
Placebo QD
10 mg QD
20 mg QD
5 mg QD
2 mg QD
HbA1C levels (%)
Time frame: 12 weeks
Evaluation of Dose Response in HbA1c (%)
Time frame: 12 weeks
Insulin and Glucose AUC following a mixed meal tolerance test
Time frame: 12 weeks
Proportion of subjects achieving ADA glycemic goal of Hb A1c <7%
Time frame: 12 weeks
Incidence of Adverse Events
Time frame: 12 weeks
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer